title: Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?
authors.affiliation: Urban Health Study, Institute for Health Policy Studies, University of California, San Francisco 94110, USA. bredlin@itsa.ucsf.edu
authors.forename: B R
authors.initials: BR
authors.lastname: Edlin
authors.forename: K H
authors.initials: KH
authors.lastname: Seal
authors.forename: J
authors.initials: J
authors.lastname: Lorvick
authors.forename: A H
authors.initials: AH
authors.lastname: Kral
authors.forename: D H
authors.initials: DH
authors.lastname: Ciccarone
authors.forename: L D
authors.initials: LD
authors.lastname: Moore
authors.forename: B
authors.initials: B
authors.lastname: Lo
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004992:Ethics, Medical; D006291:Health Policy; D006526:Hepatitis C / Q000150:complications* / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007372:Interferons / Q000009:adverse effects / Q000627:therapeutic use*; D018447:Medical Futility; D010349:Patient Compliance; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011287:Prejudice; D012008:Recurrence; D012306:Risk; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000628:therapy; D019966:Substance-Related Disorders / Q000150:complications / Q000628:therapy; D014481:United States / Q000453:epidemiology; D028761:Withholding Treatment
chemical_list: D000998:Antiviral Agents; D007372:Interferons